Related Experiment Video
Updated: Jul 1, 2025
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.3K
Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer
Regina Wachuka Mbugua1, Atsushi Takano1, Bayarbat Tsevegjav1
1Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan.
International Journal of Oncology
|March 1, 2024
Summary
Kinesin family member 20B (KIF20B) is highly expressed in breast cancer and linked to poor prognosis. Silencing KIF20B inhibits cancer cell growth and invasion, suggesting it as a potential biomarker and therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer remains a leading cause of cancer death despite treatment advances.
- Novel biomarkers and therapeutic targets are crucial for effective breast cancer management.
- Kinesin family member 20B (KIF20B) was identified as a potential candidate due to its expression patterns.
Purpose of the Study:
- To investigate the role of KIF20B as a biomarker and therapeutic target in breast cancer.
- To analyze KIF20B expression levels in breast cancer tissues and cell lines.
- To evaluate the impact of KIF20B on breast cancer cell proliferation, survival, and invasion.
Main Methods:
- Gene expression profiling and preliminary screening.
- Reverse transcription-quantitative PCR and Western blotting for KIF20B mRNA and protein.
- Immunohistochemical staining of tissue microarrays.
- Small interfering RNA (siRNA) for KIF20B knockdown.
- Matrigel cell invasion assays.
Main Results:
- KIF20B was highly and frequently expressed in all breast cancer subtypes and cell lines, but not in normal tissues.
- Strong KIF20B expression correlated significantly with advanced pathological N stage and worse patient prognosis.
- KIF20B knockdown inhibited breast cancer cell proliferation, induced apoptosis, and reduced invasiveness.
Conclusions:
- KIF20B is an oncoprotein overexpressed in malignant breast cancer.
- KIF20B is an independent prognostic factor and a potential biomarker for breast cancer.
- KIF20B represents a promising molecular target for novel breast cancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:26NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K